Immunophotonics is a biotech company developing a proprietary carbohydrate polymer (N-dihydrogalactochitosan or "GC").
GC's Key Highlights
- Turns a common local tumor ablation into a systemic immunotherapy for cancer, targeting both local tumors and distant metastases
- Potential to improve outcomes of the large number of annual tumor ablation procedures
- Off-the-shelf drug with low COGS, simple administration and reproducible manufacturing
- Potential synergy with recently approved cancer immunotherapies such as anti-PD-1 and anti-CTLA4
- GC is intended to be injected immediately after an approved ablation
- Favorable safety profile allowing potential development in both early and late stage cancers
- Significant clinical unmet need and market opportunity
GC Transforms Local Tumor Ablation into Systemic Immunotherapy
GC is a novel compound that is intratumorally injected after local tumor destruction (such as tumor ablation), utilizing the whole repertoire of tumor associated neoantigens availabe in situ for the immune system after (1) ablation-based immunogenic cell death by (2) localizing these antigens on site, thus making them accessible to the immune system, and (3) enhancing their uptake by Antigen-Presenting Cells (APC), and (4) promoting APC activation through interaction with GC. Collectively, (5) a systemic antitumor response is initiated.
Effective Across Many Ablation Techniques
GC is procedure-agnostic as its efficacy has been demonstrated in preclinical models following treatment with a variety of ablation techniques including photodynamic therapy, thermal laser, and high intensity focused ultrasound.
Clinical Synergy with Existing Immunotherapies
Importantly, a prominent tumor-specific T-cell response induced by GC injection can prime the patient to be more responsive to downstream immuno-oncology therapies, thus ultimately improving their clinical efficacy. This is an opportunity as many immunotherapies would benefit from higher response rates. Immunophotonics plans to conduct further studies exploring alternative options of combining GC with other checkpoint inhibitors.